Pathalys Pharma News Today

/PRNewswire/ -- Catalys Pacific, a transpacific life science investment firm, and SR One, a transatlantic life sciences investment firm, today announced the...

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“

All the makers of the 10 drugs subject to the inaugural Medicare drug price negotiations have opted into the talks with CMS.

GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with

GAITHERSBURG, Md., Oct. 02, 2023 -- Emergent BioSolutions Inc. today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial...

State budget negotiators are weighing $1.4 billion for NCInnovation, a private, non-profit aimed at providing grants to commercialize university or research.

The Senate budget proposal allocates $1.425 billion to NCInnovation, a non-profit aimed at fostering innovation and economic growth in the state.

Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track - Formal Notification Received of Sebetralstat EU Orphan Drug Status - KalVista Pharmaceuticals, Inc.